( HORSHAM Pa.--(BUSINESS WIRE)--Jul 9 2...)Neose Technologies to Present at C.E. Unterberg, Towbin Emerging,Growth Opportunities Conference,Health

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 9, 2007 - Neose Technologies, Inc. (NasdaqGM:NTEC) announced today that it will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference held at the Mandarin Oriental Hotel in New York City from July 10-12, 2007. The Company's presentation is scheduled for 2:00 p.m. (EDT) on Tuesday, July 10, 2007. The presentation will be webcast live and available for replay via the following link:

http://www.wsw.com/webcast/ceut6/ntec/

The webcast will also be available on the Investor Relations/Audio Archives page of the Company's website, www.neose.com.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of $15 billion.

For more information, please visit www.neose.com.

Contact

Neose Technologies, Inc.
A. Brian Davis
Sr. Vice President and Chief Financial Officer
or
Barbara Krauter
Manager, Corporate Communications
215-315-9000

'"/>




Page: 1
Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
6. Micell Technologies Presents Data on Novel Drug-Eluting Stents
7. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
8. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
9. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
10. The Past, Present and Future of HLA Typing
11. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis